<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113603</url>
  </required_header>
  <id_info>
    <org_study_id>201701984A3</org_study_id>
    <nct_id>NCT04113603</nct_id>
  </id_info>
  <brief_title>Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography</brief_title>
  <official_title>Comparison of Diagnostic Performance of Urothelial Carcinomas Between Single-bolus and Split-bolus Computed Tomography Urography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-bolus computed tomography urography (CTU)is a recently developed one-stop imaging
      examination for diagnosis of urinary tract diseases, including urinary malignancies. However,
      single-bolus CTU uses two post- contrast phases (i.e.: nephrographic and excretory phases)
      for diagnosis of urinary tract diseases. A further-developed split-bolus CTU uses solitary
      post-contrast phase containing mixed information of nephrographic and excretory phases for
      diagnosis of urinary tract disease; however, whether split-bolus CTU has similar high
      diagnostic values for urinary malignancies remains unaddressed. Thus, the aim of this study
      is to compare the diagnostic performance between single-bolus and split-bolus CTU for
      diagnosing urinary malignancies. This study will enroll 352 patients from two hospitals if
      they fit the including criteria including aged &gt; 40 years old, presenting with gross
      hematuria or having urinary malignancies histories, normal renal function (i.e.: estimated
      glomerular filtration rate &gt; 60 mL/min/1.73 m2, no allergic history to iodinated contrast
      medium and no pregnancy). All enrolled patients will be randomized to undergo split-bolus and
      single-bolus CTU in 1: 1 manner. Two radiologists will read CTU images independently using a
      standardized recording sheet with Likert scales 1-5 representing higher probabilities of
      presence of urinary malignancies for larger number). The diagnostic values of split-bolus and
      single-bolus CTU will analyzed using reference standards by final diagnoses of urinary
      malignancies (i.e.: presence of urinary malignancies based on histological examinations of
      cytology examinations, biopsies or surgical specimens). The diagnostic performance of
      split-bolus CTU and single- bolus CTU for urinary malignancies will be compared using areas
      under receiver operating curve (ROC) to determine whether there is presence of significant
      difference .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 352 patients. The calculation of sample size is according to the
      following equation:

      n2=〖(Z∝+Zβ/2)〗^2/〖(δ-|ε|)〗^2 [p1(1-p1)/k+p1(1-p2)]

      ∝=0.05, β=0.2, δ=0.05, p1=0.96, p2=0.80 Then, the number of each arm patient should be ≥ 141
      patients. However, if 20 % of the enrolled patients by fitting inclusion criteria are
      excluded by fitting exclusion criteria, the number of each arem should be ≥ 176 patients.
      Thus, this study plans to enroll 352 patients (for two arms). The enrolled patients are
      randomized to two groups (using single-bolus CTU versus using split-bolus CTU) using permuted
      block method.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic values of urothelial carcinoma</measure>
    <time_frame>3 years</time_frame>
    <description>sensitivity, specificity, accuracy, area under ROC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>radiation dose</measure>
    <time_frame>3 years</time_frame>
    <description>radiation dose of single bolus versus split bolus CTU</description>
  </secondary_outcome>
  <other_outcome>
    <measure>diagnostic values of other urinary tract diseases</measure>
    <time_frame>3 years</time_frame>
    <description>sensitivity, specificity and accuracy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>A_Single bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single bolus computed tomography urography (CTU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_Split bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Split bolus computed tomography urography (CTU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urinary malignancy</intervention_name>
    <description>Single bolus three phase CTU</description>
    <arm_group_label>A_Single bolus</arm_group_label>
    <arm_group_label>B_Split bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Fitting all of the followings

          1. age ≥ 40 years old

          2. presenting with gross hematuria or having a history of urothelial carcinomas

          3. normal renal function (i.e.: estimated glomerular filtration rate ≧ 60 mL/min/1.73 m2)

          4. no allergy history of iodinated contrast medium

        Exclusion Criteria: Fitting any of the followings

          1. pregnant or lactating woman

          2. withdrawal of informed consent

          3. no completion of CTU study

          4. no established final diagnosis or follow up duration less than 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Jen Wang, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Jen Wang, M.D., M.P.H.</last_name>
    <phone>886975365759</phone>
    <email>lijenwang0918@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yon-Cheong Wong, M.D.</last_name>
    <phone>886975365758</phone>
    <email>wongyoncheong@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Li-Jen Wang</name>
      <address>
        <city>Taoyuan</city>
        <state>Ta</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Jen Wang, M.D., M.P.H.</last_name>
      <phone>886975365759</phone>
      <email>lijenwang0918@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yon-Cheong Wong, M.D.</last_name>
      <phone>886975365758</phone>
      <email>wongyoncheong@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan to make individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

